Altimmune to Attend Two Upcoming Investor Conferences

Altimmune, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq (ALT), announced that its management team will participate in several upcoming investor conferences. These events include the Jefferies Global Healthcare Conference in New York, NY, scheduled for June 5, 2024, and the Goldman Sachs Global Healthcare Conference in Miami Beach, FL, on June 12, 2024. During these conferences, Altimmune’s management will hold Fireside Chats, with the Jefferies session at 2:00 p.m. Eastern Time and the Goldman Sachs session at 9:20 a.m. Eastern Time. Both sessions will be webcast, and interested parties can access them through the Events section on Altimmune’s official website.

Altimmune specializes in developing next-generation peptide-based therapeutics. One of their primary focuses is the development of pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity and MASH (Metabolic Associated Steatohepatitis), which are significant health concerns. 

Altimmune is dedicated to pushing the boundaries of biopharmaceutical advancements and is continually involved in research and development to bring innovative treatments to market. The forthcoming participation in these investor conferences underscores the company’s commitment to engaging with the investment community and sharing their progress and strategic direction.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!